A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

NCT06678555 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Lorlatinib

Sponsor

Pfizer